CamBMT1: A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases (mets) for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy.
Baird, R Garcia-Corbacho, J Ramenatte, N Jonson, A Ahmad, S Smith, D Qian, W Kumar, S Linossi, C Matys, T
Baird, R
Garcia-Corbacho, J
Ramenatte, N
Jonson, A
Ahmad, S
Smith, D
Qian, W
Kumar, S
Linossi, C
Matys, T
Citations
Altmetric:
Abstract
Description
Date
2016-10-01
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
CamBMT1: A proof-of-principle phase 1b / randomised phase 2 study of afatinib penetration into brain metastases (mets) for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy. 2016, 27 (suppl 6):408TiP Annals of Oncology